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INTRODUCTION 66
Lobular carcinoma in situ (LCIS) is a pre-invasive lesion of the breast, which is often multifocal and 67 bilateral (1). Over the last three decades, LCIS has been clinically perceived as a risk indicator and 68 managed accordingly (1). There is, however, burgeoning phenotypic and genetic evidence to suggest 69 that LCIS is a non-obligate precursor of invasive breast cancer, akin to ductal carcinoma in situ (DCIS) 70
(2). 71 72 LCIS and invasive lobular carcinomas (ILCs) are phenotypically and genetically similar. Both lesions 73 are preferentially of the luminal A molecular subtype (i.e. estrogen receptor (ER)-positive, HER2-74 negative, low-grade and low-proliferation), and harbor recurrent gains of 1q and losses of 16q, 75 encompassing the CDH1 gene locus, as well as recurrent CDH1 somatic mutations (1, (3) (4) (5) (6) (7) . In fact, loss 76 of E-cadherin, the protein product of the CDH1 gene, is a hallmark feature of these lesions (3, 6) and 77 has been shown to result in the development of ILCs in conditional mouse models (8) . Analyses of the 78 genomic features of ILCs by The Cancer Genome Atlas consortium (TCGA) (6) and individual 79 investigators (9) have revealed the genes most commonly mutated in this subtype of breast cancer, 80 and identified molecular differences between invasive ductal carcinomas (IDCs) of no special type and 81
ILCs, including a higher rate of FOXA1 mutations and a lower rate of GATA3 mutations in those with 82 lobular histology. Additional whole-exome (WES) (7) and targeted (10) Previous studies have demonstrated that synchronous LCIS and invasive breast cancers may be 87 clonally related and share a common ancestral lesion (4, 7, 10) . In most studies, however, clonal 88 relatedness was inferred using limited genomic information derived from copy number (4) or targeted 89 sequencing analyses (10). By combining copy number and WES data, Begg et al. provided evidence of 90 clonal relatedness between LCIS and associated lesions (7) . These studies, however, did not 91 6 investigate the basis of the clonal relatedness between LCIS and ILC, and whether the progression 92 from LCIS to ILC would involve the selection of specific subclones or happen through multiclonal 93 invasion (11, 12) . Given that not only invasive breast cancers (13) but also pre-invasive lesions (11) 94 may be genetically heterogeneous at diagnosis, and that tumor progression/stromal invasion may stem 95 from clonal selection (11, 13) , it is plausible that LCIS may display intra-lesion genetic heterogeneity 96 and that the progression from LCIS to more clinically advanced lesions, such as DCIS or invasive 97 breast cancer, may result from the selection of pre-existing subclones. 98 99 Here, we performed a re-analysis of WES data generated from a unique series of frozen LCIS samples 100 from prospectively accrued, consecutive patients subjected to prophylactic or therapeutic mastectomy, 101 previously published by Begg et al. (7) . We performed a high-depth targeted capture sequencing 102 validation of the mutations identified by WES in that study, using the same DNA samples and employed 103 state-of-the-art bioinformatics algorithms with a Bayesian clustering model (PyClone) to infer subclone 104 structure and with construction of clone based phylogeny, seeking to define the clonal composition and 105 mutational processes in LCIS synchronously diagnosed with ILC, DCIS and/or IDC, and to ascertain 106 whether changes in the clonal composition are observed in the progression from LCIS to DCIS or ILC. 107 8 A validation of the mutations found with WES was performed for cases with sufficient DNA material 144 (n=11), using a custom designed AmpliSeq panel on an Ion Torrent Personal Genome Machine. This 145 validation was not included in Begg et al. (7) . Out of 4,061 somatic mutations identified by WES, 1, 796 146 were investigated in five LCIS, five DCIS, eight ILCs, and two IDCs from cases 1, 2, 4, 7, 8, 10, 11, 12, 147 13, 14 and 15. 1,492 (83%) mutations were successfully validated. Mutations that had sufficient 148 coverage in the validation experiment (minimum of 50 reads) but were not validated (allele frequency 149 <1%) were excluded from the list of mutations used in the downstream analyses. 150 151
Clonality analysis 152
To infer the clonal relatedness between synchronous lesions, we defined the "clonality index" (CI) as 153 the probability of two lesions sharing mutations not expected to have co-occurred by chance based on 154 a previously validated method (25) (Supplementary Methods). 155 156
Clonal frequencies 157
To estimate the clonal architecture and composition of the lesions from each patient, mutant allelic 158 fractions from all somatic mutations were adjusted for tumor cell content, ploidy, local copy number and 159 sequencing errors using PyClone, as previously described (26) Kandoth et al. (20) and/or Cancer Gene Census (21); n=745) 207 in the genes with truncal mutations (n=559) and branch mutations (n=2,452). For the hypergeometric 208 test, the total number of genes in the genome used was 18,986, as defined as the number of protein-209 coding genes by the HUGO Gene Nomenclature Committee. The representation (enrichment) factors 210 and the P-values of the hypergeometric tests were provided for the analyses performed. All tests were 211 two-sided and P-values<0.05 were considered statistically significant, adjusted for multiple 212 comparisons where specified. 213
214

RESULTS
215
LCIS displays a repertoire of somatic genetic alterations consistent with those of ILCs and 216 luminal A-like breast cancers 217
This study consists of a re-analysis of previously described WES data (7), followed by a previously 218 unpublished targeted amplicon sequencing validation of approximately 1,800 selected mutations, from 219 43 LCIS and synchronous DCIS (n=9), ILCs (n=13) or IDCs (n=5) from 24 patients ( Table 1) . Three 220 11 patients underwent bilateral mastectomy, one was therapeutic for bilateral breast cancer and two 221 patients underwent contralateral prophylactic mastectomy; these three patients were found to have 222 bilateral LCIS ( Table 1) . All LCIS lesions were of classic type and all DCIS were of intermediate nuclear 223
grade. For those patients with invasive lesions, tumor size and ER, PR and HER2 status in invasive 224 tumor cells are described in Table 1 . Notably, all invasive carcinomas were ER-positive/HER2- inactivation is a driver of lesions with lobular histologic features (1), we observed pathogenic mutations 234 affecting the CDH1 gene in 35 of 43 (81%) LCIS, of which all but three were somatic; patient 13, who 235 had three distinct foci of LCIS, was found to harbor a CDH1 germline mutation. All but two CDH1 236 mutations were coupled with loss of heterozygosity (LOH) of the wild-type allele (77% (33/43) of all 237 LCIS analyzed, Fig. 1A) . Moreover, all LCIS cases lacked E-cadherin expression by 238 immunohistochemical analysis. LCIS lacking CDH1 mutations did not harbor mutations or deletions 239 affecting genes coding for additional proteins that comprise the cadherin-catenin complex, such as 240 CTNNB1 (β-catenin), CTNNA1 (α-catenin) or CTNND1 (p120-catenin), nor somatic or germline genetic 241 alterations in RHOA (Supplementary Data File 1) , a gene that has been implicated in the biology of 242 gastric cancer (35), and whose alterations result in neoplastic cells displaying discohesiveness akin to 243 that caused by CDH1 loss of function. 244
12
Additional genes identified by TCGA to be significantly mutated in ILCs (6), such as PIK3CA, TBX3, 246 FOXA1 and MAP3K1, were also found to be recurrently somatically mutated in LCIS (Figs. 1A and 247 2E); however, TP53 somatic mutations, and PTEN somatic mutations and homozygous deletions, 248 present in 8%, 7%, and 6% of ILCs analyzed by TCGA (6), were not found in any of the LCIS analyzed 249 here. Notably, TP53 mutations were significantly more frequently found in luminal A invasive breast 250 cancers from TCGA than in the LCIS analyzed here (12% (25/209) vs 0% (0/43), Fisher's exact test, 251 P=0.019, Fig. 2E ). Moreover, genes identified by TCGA to be significantly mutated in luminal A 252 invasive breast cancers, including CBFB, GATA3, NCOR1 and MED23 were also found be recurrently 253 mutated in LCIS. Interestingly, however, CBFB was found to be mutated in 19% (8/43) of LCIS, a rate 254 significantly higher than that in 2% (2/127) of ILCs and 2% (5/209) of luminal-A breast cancers from 255 TCGA (Fisher's exact tests, P<0.01, Fig. 2E ). Gene CNA analysis revealed recurrent losses of 16q and 256 gains of 1q ( Fig. 1B) , a pattern also observed in ILCs (4,6) and luminal-A invasive breast cancers (31). 257
Taken together, our findings demonstrate that LCIS synchronously diagnosed with more advanced 258 lesions in this study is a genetically-advanced, neoplastic lesion often driven by E-cadherin loss of 259 function, with a spectrum of somatic genetic alterations affecting genes commonly altered in ILCs and 260 luminal-A invasive breast cancers. 261
262
LCIS is often clonally-related to DCIS and ILCs 263
WES of nine DCIS (a non-invasive precursor lesion perceived clinically to be more advanced than LCIS 264 (36,37)), 13 ILCs, and five IDCs collected synchronously with the LCIS analyzed above demonstrated 265 that overall these lesions displayed similar number of mutations/case, mutation rates, repertoires of 266
CNAs and non-synonymous somatic mutations to those of the LCIS analyzed in this study ( Fig. 1, 2A -267 D), with exception of CDH1 somatic mutations that were exclusively found in LCIS and ILCs. 268
269
We reasoned that the somatic mutations and CNAs found in anatomically distinct foci of LCIS, ILC, 270 DCIS and IDC could provide a basis for defining their clonal relatedness. Consistent with the analysis 271 13 reported by Begg et al. (7), but based on distinct bioinformatics and biostatistical approaches 272 (Supplementary Methods), here we demonstrate that all multifocal LCIS originating in the same breast 273 quadrant (8/8 samples, four patients; cases 4, 7, 9, 23) were clonally-related, harboring several 274 identical somatic mutations and CNAs (Fig. 3A, Supplementary Figs. S1-S3 ). Sixty-seven percent 275 (16/24) of multifocal LCIS affecting distinct quadrants of the breast were also clonally-related (Fig. 3A) . 276
Further, 10/13 (77%) ILCs and 5/9 (56%) DCIS samples were found to be clonally-related to at least 277 one synchronous LCIS analyzed (Fig. 3A) . Interestingly, none of the five IDCs studied were found to be 278 clonally-related to a LCIS (Fig. 3A) , however, in all three cases where synchronous DCIS and IDC 279 samples were analyzed, the DCIS and IDC were found to be clonally-related ( Fig. 3A, Supplementary  280 Figs. S1-S2). As expected, no clonal relatedness was observed between lesions arising in distinct 281 breasts (bilateral cases; Fig. 3A, Supplementary Figs. S1-S2 ). In addition, the clonal relatedness 282 and that the presence of these lesions in distinct quadrants of the breast does not predict their clonal 287 relatedness. LCIS and synchronous DCIS and/or ILC are often clonally-related, corroborating the notion 288 (4,7,38,39) that LCIS is a non-obligate precursor of more clinically-advanced lesions, in particular ILCs. 289
Furthermore, no evidence of clonality between LCIS and IDC was observed here, suggesting that direct 290 progression from CDH1-mutant LCIS to IDC is an uncommon biological phenomenon. 291
292
LCIS foci displaying intra-lesion genetic heterogeneity are more likely to progress to ILCs 293
Recent studies have demonstrated that intra-tumor genetic heterogeneity may be present in non-294 invasive lesions including DCIS (11,40) and pre-invasive lesions arising in other organs (e.g. of the 295 esophagus)(41). In such cases, all neoplastic cells harbor the founder genetic events (i.e. truncal 296 mutations) and subclonal populations of cancer cells display additional genetic alterations (i.e. branch 297 14 mutations)(42). We posited that LCIS would harbor intra-lesion genetic heterogeneity and that LCIS 298 lesions when clonally-related to DCIS or ILC would be associated with a higher level of intra-lesion 299 genetic heterogeneity than LCIS not clonally-related to more advanced lesions. 300
301
To test this hypothesis, we resolved the clonal composition of LCIS, DCIS and/or ILC samples by 302 applying a Bayesian clustering model (PyClone (26)) to mutant allele fractions, incorporating tumor 303 cellularity, ploidy and local copy number obtained from ABSOLUTE (24) S4A-B) . These findings were further corroborated by an analysis of the Shannon and Gini-Simpson 308 diversity indices (27, 28, 43) , which demonstrated that as a group LCIS clonally-related to DCIS and/or 309 ILC (n=18) displayed significantly higher intra-lesion genetic heterogeneity than LCIS not clonally-310 related to more advanced lesions (n=25) (Mann-Whitney U test, P=0.005, Fig. 3B-C, Supplementary  311 Figs. S4C-D). Interestingly, in case 4, composed of two LCIS and one ILC, all sharing a common 312 ancestor, the LCIS lesion displaying heterogeneity was found to be the likeliest direct precursor of the 313 ILC ( Fig. 4A) . 314
315
Given the intra-lesion genetic heterogeneity observed in LCIS, in particular in those related to more 316 advanced lesions, we sought to define whether the branch mutations found in these lesions would 317 affect 'passenger' genes or genes significantly mutated in cancer (20) (21) (22) . Contrary to the notion that 318 heterogeneity would primarily affect passenger genetic events, both truncal and branch non-319 synonymous somatic mutations detected in LCIS clonally-related to the other lesions were found to 320 target genes significantly enriched for known cancer drivers (20-22) (hypergeometric test, 321 representation factor=2.09, P<0.01, and hypergeometric test, representation factor=1.5, P<0.01, 322 respectively; Supplementary Figs. S4E-F) . Importantly, however, in agreement with previous multi-323 15 region analyses that suggested that most of the driver genetic alterations are early truncal events 324 (13,16,44), the enrichment for cancer genes was higher in the constellation of truncal than in branch 325 mutations. Truncal mutations included genes found to be significantly mutated in ILCs and/or luminal-A 326 invasive breast cancers, including CDH1, PIK3CA, MAP3K1, CBFB, SF3B1, RUNX1 and FOXA1 327 (Supplementary Data File 1) , whereas branch mutations included GATA3, PIK3CA, ERBB2 and 328
KMT2C. 329 330
Given the clonal relatedness of LCIS with DCIS and ILC, we posited that progression from LCIS to 331 DCIS/ILC could result in the selection of specific subclones harboring private genetic alterations 332 (11, 12, 40) . In 29% (4/14) of cases where LCIS was clonally-related to DCIS or ILC, we observed that a 333 selected population from the LCIS became dominant in the respective DCIS or ILC (Fig. 4,  334   Supplementary Fig. S1) , whereas in the remaining 10 cases our findings suggested parallel 335 progression between LCIS, DCIS and/or ILC. In two cases (cases 4 and 10), a minor subclone from a 336 LCIS was the likeliest substrate for the development of the DCIS or the ILC (Fig. 4) . In cases 1, 11 and 337 16, the biological chronology of the LCIS and DCIS could not be resolved on the basis of the 338 sequencing data available (Supplementary Fig. S1) . Analysis of the genes affected by branch somatic 339 mutations restricted to, or enriched in, the DCIS/ILC samples clonally-related to LCIS revealed that in 340 the progression from LCIS to DCIS or ILC, known cancer driver genes were affected by somatic 341 mutations (e.g. MAP3K1 (2 cases), RUNX1, NCOR1, ARID1A and TBX3 (2 cases)) or LOH of the wild-342 type allele ( Figs. 1 and Supplementary Fig. S4F, Supplementary Data File 1) . 343 344 Taken together, our results demonstrate that LCIS clonally-related to DCIS/ILC more frequently 345 displays intra-lesion genetic heterogeneity than LCIS not clonally-related to more advanced lesions, 346 that both truncal and branch mutations are enriched for known cancer drivers, and that known cancer 347 genes are likely targeted by somatic genetic events in the progression from LCIS to more clinically 348 advanced lesions. 349 16 350
Shifts in mutational processes are linked to progression from LCIS to DCIS and ILCs 351
There is evidence to suggest that the mutational processes that shape the mutational spectra of tumors 352 may change during evolution (16, 45) . Hence, we sought to define whether changes in mutational 353 spectra were observed in the transition from LCIS to DCIS/ILC. Given that truncal mutations are likely 354 reflective of biological phenomena that took place prior to or during the development of LCIS, and that 355 branch mutations in DCIS/ILC likely stem from mutational processes involved in tumor maintenance 356 and progression, we compared the mutational spectrum of truncal and branch mutations in cases 357
where LCIS was clonally-related to DCIS/ILC. Both truncal and branch mutations were found to be 358 enriched for C>T transitions in the NpCpG context, consistent with a signature ascribed to aging (46), 359
and C>G transversions and C>T transitions in the TpCpW context, suggestive of the mutational 360 processes caused by APOBEC DNA cytosine deaminase activity (47); the latter being predominately 361 found in the branch mutations of case 4 ( Fig. 5A) and emerging in the DCIS of case 1 and ILC of case 362 18 ( Fig. 5B-C) . Akin to the variations in mutational processes observed in the progression of other 363 cancer types (29,45), in-depth analysis of cases 1, 4 and 18 revealed that a mutational process 364 consistent with the APOBEC signature was active in the progression from LCIS to DCIS or ILC (Fig. 5) . 365
Moreover, the mRNA levels of APOBEC3B, a DNA cytosine deaminase that has been causally 366 implicated in the development of APOBEC signature mutations in cancer (47,48), were significantly 367 higher in samples displaying an APOBEC mutational process than in those displaying an aging 368 signature (Fig. 5D) . These observations combined to indicate that, at least in a subset of cases, the 369 APOBEC mutational process is likely to be contributing to the development of more advanced lesions. 370
371
DISCUSSION 372
Here we provide direct evidence of the neoplastic and non-obligate precursor nature of at least a 373 subset of LCIS. By performing a clonal decomposition and clonal relatedness analysis of LCIS and 374 synchronously diagnosed DCIS, ILCs and/or DCIS, we have observed that LCIS can display intra-375 lesion genetic heterogeneity and be clonally-related to DCIS and ILCs, whereas progression from LCIS 376 to IDC is likely a rare event. Notably, LCIS clonally related to ILCs and/or DCIS were found to display 377 higher levels of intra-lesion genetic heterogeneity than LCIS that were not clonally related to a more 378 advanced lesion, and evidence of clonal selection in the progression from LCIS to ILCs and/or DCIS 379 was documented in a subset of patients. In these patients, the APOBEC mutational process, which has 380 been implicated in genetic instability and intra-tumor genetic heterogeneity, appears to be present later 381 in the evolution of LCIS and may be involved in its progression to more advanced lesions. Interestingly, 382 the samples enriched for APOBEC mutation process displayed higher expression levels of 383 APOBEC3B, whose activity has been shown to be mutagenic (47). Therefore, one hypothesize that in a 384 subset of LCIS, upregulation of APOBEC3B results in increased mutagenesis and intra-tumor genetic 385 heterogeneity, ultimately promoting subclonal expansions and progression to ILC. 386 387 LCIS has been historically considered a less advanced lesion as compared to DCIS, and is usually 388 managed conservatively, not mandating surgical excision (1). Accordingly, in the latest version of the 389 TNM staging system, LCIS is no longer staged as an in situ carcinoma (pTis) as DCIS is (49). It should 390 be noted that although we detected clonal relatedness between LCIS and DCIS, and the LCIS as the 391 potential substrate for the development of the DCIS (i.e. case 10), the directionality of the evolution was 392 not clear in three cases (i.e. cases 1, 11 and 16). Hence, we cannot rule out the possibility that in a 393 subset of cases, LCIS may have arisen from a preexistent DCIS or a common precursor (e.g. flat 394 epithelial atypia). In fact, due to the molecular similarities between low-grade LCIS and DCIS (2), 395 inactivation of CDH1 in a DCIS subclone would be the likeliest explanation for such a phenotypic shift. 396
Bi-directional progression between lesions of lobular (atypical lobular hyperplasia and LCIS) and ductal 397
phenotype (atypical ductal hyperplasia and DCIS) is entirely consistent with the proposed concept of a 398 low nuclear grade breast neoplasia family (2), which encompasses a group of low-grade, ER-positive 399 neoplasms of the breast that not uncommonly affect the same segment of the breast, if not the same 400
terminal ductal-lobular unit, and share a remarkably similar genomic landscape, having concurrent 1q 401 gains and 16q losses, and PIK3CA mutations, as their genetic signature (2). Alternatively, both LCIS 402 and DCIS might arise from a common precursor (i.e. case 1), such as flat epithelial atypia (2). Taken 403 together, these findings support the notion that the progression of LCIS and DCIS might be 404 bidirectional, or that these lesions may evolve in parallel from a common ancestor. 405
406
Our findings demonstrate that LCIS displays a genomic landscape comparable to that of invasive 407 breast cancers of luminal A subtype (31) and/or of lobular histology (6), lesions unequivocally more 408 advanced and that mandate therapeutic intervention. Akin to ILCs (6), LCIS harbors recurrent bi-allelic 409 inactivation of CDH1 (77%), and recurrent mutations affecting genes commonly mutated in breast 410 cancer, including PIK3CA, FOXA1 and TBX3, among other genes. It should be noted, however, that 411 genetic alterations affecting TP53 and PTEN, previously found as recurrent events in ILCs (6), were not 412 identified in the LCIS samples analyzed in this study. These differences might be related to the fact that 413 our cohort included only classic LCIS, but given that progression may occur via clonal selection, and 414 that not only truncal, but also branch mutations are enriched for known cancer genes, it is plausible that 415 acquisition of genetic alterations, including those resulting in inactivation of these two bona fide tumor 416 suppressor genes, may play a role in the progression to ILC. Indeed, we (7,11) and others (13) have 417 demonstrated previously that loss of PTEN may be associated in the progression from DCIS to IDC. 418
419
The finding that LCIS is unlikely clonally-related to IDCs is in contrast with previous publications, 420
including that from Begg et al. (7), who reported two LCIS lesions clonally-related to IDCs based on a 421 limited number of shared mutations (one and three mutations in Patients 9 and 14, respectively), which 422 is substantially lower than the number of shared mutations observed in clonally-related LCIS-ILC or 423 LCIS-DCIS lesions in this study (median 12, range 2-171). The mutations described by Begg et al. (7) 424 found to be shared between LCIS and IDC samples may have constituted sequencing artifacts, 425 germline mutations or common single nucleotide polymorphisms (SNPs) ( Supplementary Table S2 , 426
Supplementary Data File 1), as they were filtered out in our more conservative somatic mutation 427 19 analysis. Although we did not detect direct clonal relatedness between LCIS and IDC in this study, we 428 cannot rule out the possibility that a subset of synchronous IDC and LCIS may share a common early 429 precursor or that ductal lesions and LCIS may arise from a common earlier precursor lesion and 430 undergo parallel evolution. In addition, it is also plausible that a subset of LCIS may stem from DCIS 431 harboring 16q losses, but the CDH1 inactivation takes place later in the evolution of the lesion. 432
433
Although our findings define LCIS as a non-obligate precursor of ILC, they do not imply that changes in 434 the clinical management of patients presenting with LCIS are necessary, as the rate of subsequent 435 breast cancer development in a large cohort of patients with a diagnosis of LCIS as reported by the 436 SEER database demonstrates a risk of approximately 1% per year (50). Nonetheless, our study might 437 provide a framework for the identification of markers to define LCIS cases that have a greater likelihood 438 to progress. Although some of the pathologic characteristics of LCIS, such as volume of disease, are 439 associated with a greater likelihood of progression to DCIS/ILC, there has yet to be a validated 440 biomarker to predict the behavior of classic LCIS. Based on our results, one could posit that assessing 441 the levels of intra-lesion genetic heterogeneity and/or APOBEC3B activity in LCIS may help select 442 patients that should be counseled more proactively towards surgical excision and/or hormonal 443 chemoprevention, akin to the current management of low-to intermediate-grade DCIS. Increasingly, 444 treatment of early ER-positive breast cancer relies on pathologic features, tumor burden and genomic 445 profiles; our findings suggest that with continued investigation a combination of clinical features, 446 histologic classification, assessment of volume of disease and intra-lesion genetic heterogeneity may 447 allow a more personalized risk assessment for patients with LCIS. 448
449
Our study has important limitations. The prospective accrual of frozen samples of LCIS adequate for 450 detailed molecular studies is remarkably challenging; hence the sample size of the present study is 451
small. In addition, our study may not be representative of incidental cases of LCIS, given that the 452 patients included in this study were accrued in a prospective protocol for the multiregional sampling of 453 20 prophylactic and/or therapeutic mastectomies from patients with a previous diagnosis of LCIS. 454
Moreover, we only performed WES analysis, hence we cannot rule out that non-coding alterations 455 and/or epigenetic changes may play a role in the development and progression of LCIS. More 456 comprehensive analyses may also be required to define the alternative drivers of CDH1 wild-type LCIS. 457
Finally, we used tumor bulk sequencing and state-of-the-art computational approaches to infer the 458 clones present in each sample/case and their phylogeny. Single-cell sequencing analyses of LCIS and 459 synchronous lesions are warranted to confirm our findings and provide direct evidence of the clonal 460 composition of LCIS and of clonal selection in the evolution to more advanced lesions. 461 462 Despite these limitations, this proof-of-principle study demonstrates that LCIS is a neoplastic non-463 obligate precursor of DCIS and ILC, with a repertoire of somatic genetic alterations similar to that of 464
ILCs and luminal-A invasive breast cancers, but lacking TP53 and PTEN mutations. LCIS at diagnosis 465 often displays intra-lesion genetic heterogeneity, and, in a subset of cases, the progression from LCIS 466 to DCIS and ILC may involve the selection of clones, which may harbor distinct active mutational 467 processes such as APOBEC. Our findings suggest that early documentation of intra-lesion genetic 468 heterogeneity may be central to developing robust molecular predictors of the risk of LCIS 469 progression/evolution into more aggressive forms of breast cancer. 
Left 50 Treeomics (30) is depicted. The mutations affecting cancer genes (colored in orange) and the hotspot mutations (colored in red) that define a given clone are illustrated alongside the branches. The length of the branches is proportional to the number of mutations that distinguish a given clone from its ancestor.
The numbers alongside the branches represent the total number of somatic mutations. 
